XML 83 R26.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Financial assets and liabilities measured at fair value | 12 Months Ended
--- | ---
Dec. 31, 2024
Fair Value Measurement [Abstract] |
Financial assets and liabilities measured at fair value | Financial assets and liabilities measured at fair value Under IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a fair value hierarchy with the following levels: •level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging); •level 2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and •level 3: valuation techniques in which not all important inputs are derived from observable market data. The valuation techniques used are described in Note B.8.5. The table below shows the balance sheet amounts of assets and liabilities measured at fair value.
|  | 2024 | 2023 | 2022
|  | Level in the fair value hierarchy | Level in the fair value hierarchy | Level in the fair value hierarchy
(€ million) | Note | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3
Financial assets measured at fair value |  |  |  |  |  |  |  |  |  |
Quoted equity investments | D.7.1. | 467 | — | — | 470 | — | — | 387 | — | —
Unquoted equity investments | D.7.1. | — | — | 1,092 | — | — | 618 | — | — | 549
Quoted debt securities | D.7.2. | 357 | — | — | 346 | — | — | 329 | — | —
Unquoted debt securities not meeting the definition of equity instruments | D.7.3. | — | — | 339 | — | — | 132 | — | — | 115
Contingent consideration relating to divestments | D.7.3. & D.11. | — | — | 286 | — | — | 214 | — | — | 303
Financial assets held to meet obligations under deferred compensation plans | D.7.3. & D.11. | 688 | — | — | 572 | — | — | 512 | — | —
Non-current derivatives | D.7. | — | — | — | — | — | — | — | — | —
Current derivatives | D.11. | — | 217 | — | — | 201 | — | — | 206 | —
Mutual fund investments | D.13. | 4,161 | — | — | 5,349 | — | — | 9,537 | — | —
Total financial assets measured at fair value |  | 5,673 | 217 | 1,717 | 6,737 | 201 | 964 | 10,765 | 206 | 967
Financial liabilities measured at fair value |  |  |  |  |  |  |  |  |  |
Bayer contingent purchase consideration arising from the acquisition of Genzyme | D.18. | — | — | — | — | — | — | — | — | 26
MSD contingent consideration (European vaccines business) | D.18. | — | — | 72 | — | — | 127 | — | — | 204
Shire contingent consideration arising from the acquisition of Translate Bio | D.18. | — | — | 568 | — | — | 441 | — | — | 380
Contingent consideration arising from acquisition of Amunix | D.18. | — | — | — | — | — | 137 | — | — | 165
Other contingent consideration arising from business combinations and acquisitions | D.18. | — | — | 1 | — | — | 4 | — | — | 4
Non-current derivatives | D.20. | — | 121 | — | — | 164 | — | — | 232 | —
Current derivatives | D.19.5 | — | 337 | — | — | 127 | — | — | 94 | —
Total financial liabilities measured at fair value |  | — | 458 | 641 | — | 291 | 709 | — | 326 | 779
No transfers between the different levels of the fair value hierarchy occurred during 2024.

X
- Definition Disclosure of financial assets and liabilities at fair value explanatory. + References No definition available. + Details
Name: | sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Measurement [Abstract] + References No definition available. + Details
Name: | sny_FairValueMeasurementAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration